FGF-23

FGF-23 Overview

English Name	Fibroblast growth factor 23	Approved Drugs	1
Drugs in Clinical Trials	1	Target Synonym	HFTC2，Tumor-Derived Hypophosphatemia Inducing Factor，UNQ3027/PRO9828，Tumor-derived hypophosphatemia-inducing factor，HYPF，FGF23，Fibroblast Growth Factor 23，Phosphatonin，FGF-23，HPDR2，PHPTC，ADHR，FGFN
Highest Development Stage	Approved

English Name	Fibroblast growth factor 23
Target Synonym	HFTC2，Tumor-Derived Hypophosphatemia Inducing Factor，UNQ3027/PRO9828，Tumor-derived hypophosphatemia-inducing factor，HYPF，FGF23，Fibroblast Growth Factor 23，Phosphatonin，FGF-23，HPDR2，PHPTC，ADHR，FGFN
Approved Drugs	1
Drugs in Clinical Trials	1
Highest Development Stage	Approved

FGF-23 Product List

Product Category
Protein (1)
Product Status
Launched (1)
Species
Human (1)
Tag
His Tag (1)
Conjugate
Unconjugated (1)

Cat. No.	Species	Host	Product Description	Structure	Purity	Feature	Order Now
FG3-H52H3	Human	HEK293	Human FGF-23 (R179Q) Protein, His Tag, low endotoxin				Add to Cart

Total: 1

FGF-23 Background

Fibroblast growth factor 23 (FGF23) is is an endocrine member of the family of FGFs and mainly produced in the bone and, upon secretion, forms a complex with a FGF receptor and coreceptor αKlotho. FGF23 can exert several endocrine functions, such as acting as a hormone on the kidney, stimulating phosphate excretion and suppressing formation of 1,25(OH)2D3, active vitamin D. Moreover, it has paracrine activities on several cell types, including neutrophils and hepatocytes. FGF23 and phosphate have been revealed to be factors relevant in cancer. FGF23 is particularly significant for those forms of cancer primarily affecting bone (e.g., multiple myeloma) or characterized by bone metastasis.

FGF-23 Synonyms

FGF23,HYPF,FGF-23,ADHR,HPDR2

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
KK-8123	KK8123; KK-8123	Phase 2 Clinical	Kyowa Kirin Inc	Familial Hypophosphatemic Rickets	Details

Marketed Drug Information

English Name	Research Code	Highest Development Stage	Company	Earliest Brand Name	Earliest Approval Country	Earliest Indication	Earliest Approval Company	Earliest Approval Date	Indication	Clinical Trial
Burosumab	KRN-23; UX-023	Approved	Kyowa Hakko Kirin Co Ltd	Crysvita, 麟平	EU	Hypophosphatemia, Familial	Kyowa Kirin Holdings Bv	2018-02-19	Familial Hypophosphatemic Rickets; Fibrous Dysplasia of Bone; Genetic Diseases, X-Linked; Hypophosphatemia; Hypophosphatemia, Familial; Nevus, Sebaceous of Jadassohn; Osteomalacia	Details